Skip to main content

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

bioRxiv logoLink to bioRxiv
[Preprint]. 2026 Apr 9:2026.04.09.717387. [Version 1] doi: 10.64898/2026.04.09.717387

The role of the innate immune system in shaping the dynamics of antimicrobial treatment

Teresa Gil-Gil, Brandon A Berryhill, Christopher Witzany, Roland R Regoes, Fernando Baquero, Bruce R Levin
PMCID: PMC13082022  PMID: 41993332

Abstract

Contemporary antibiotic treatment almost solely considers the Minimum Inhibitory Concentration (MIC) when deciding to employ an antibiotic, often overlooking the critical role of host immunity. Using Galleria mellonella and a virulent strain of Staphylococcus aureus , we investigate the infection dynamics and treatment outcomes of antibiotics of different classes—including antibiotics to which the bacteria are resistant—and a lytic bacteriophage. Surprisingly, we find that the host’s ability to control bacterial density and survive infection does not depend on the specific type of antimicrobial agent nor the bacteria’s susceptibility to it. Our results demonstrate that the innate immune system is the primary factor in therapeutic success, capable of clearing even highly resistant infections, such as those involving beta-lactamase-producing or ribosomal mutant-resistant strains. These findings challenge the traditional antibiotic-centric view of infection outcomes and emphasize the need to account for host-pathogen-drug interactions beyond simple MIC measurements when designing clinical treatment regimens.

Full Text

The Full Text of this preprint is available as a PDF (495.8 KB). The Web version will be available soon.


Articles from bioRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES